Zobrazeno 1 - 10
of 31
pro vyhledávání: '"R. Jake Jacobs"'
Publikováno v:
Revista Panamericana de Salud Pública, Vol 21, Iss 6, Pp 345-356 (2007)
OBJECTIVES: To investigate the cost-effectiveness of childhood vaccination against hepatitis A in the five geographic regions of Argentina, and to determine whether adding a second dose to the current one-dose schedule would provide health gains just
Autor:
M. Teresa Valenzuela, Bruce L. Innis, Oscar Arteaga, María S Navarrete, R. Jake Jacobs, Allen S. Meyerhoff
Publikováno v:
Vaccine. 23:4110-4119
Hepatitis A is an important public health problem in Chile. Childhood vaccination has reduced hepatitis A rates in several countries, prompting this evaluation of its cost-effectiveness in Chile. Using a Markov model, we project mass vaccination woul
Publikováno v:
Disease Management & Health Outcomes. 13(5):317-326
Introduction: A new combination vaccine, diphtheria-tetanus-acellular pertussis (DTaP)-hepatitis B (HepB)-inactivated poliovirus vaccine (IPV) [DTaP-HepB-IPV], recently became available for use in the US primary infant-vaccination series. Our objecti
Autor:
John Reitan, Gary Milkovich, Thomas A. Paivanas, Robert M. Rifkin, R. Jake Jacobs, Ronald J. Moleski, Roy A. Beveridge
Publikováno v:
Pharmacotherapy. 23:101S-109S
Objective. To quantify time expended, patient satisfaction, and econometrics associated with short-acting (sargramostim, epoetin alfa) and long-acting (darbepoetin alfa, pegfilgrastim) growth factors. Design. Retrospective resource utilization and pr
Autor:
Allen S. Meyerhoff, R. Jake Jacobs
Publikováno v:
Sexually Transmitted Diseases. 30:859-865
Background Many patients seen at U.S. sexually transmitted disease (STD) clinics are offered hepatitis B vaccination. Substituting hepatitis A/B vaccine would provide additional protection but increase costs. Goal The goal was to estimate the cost ef
Publikováno v:
Journal of American College Health. 51:227-236
Hepatitis B immunization is recommended for all American children, and hepatitis A immunization is recommended for children who live in areas with elevated disease rates. Because hepatitis A and B occur most commonly in young adults, the authors exam
Publikováno v:
The American Journal of Gastroenterology. 97:427-434
OBJECTIVES: Although hepatitis A vaccination is recommended for persons with chronic liver disease, the cost-effectiveness of vaccinating patients with chronic hepatitis C virus has not been extensively studied. We evaluated its costs and benefits. M
Publikováno v:
PharmacoEconomics. 20:739-747
Background: The cost effectiveness of hepatitis A prevention is typically assessed by comparing vaccination costs with the number of life-years saved. This endpoint does not consider the benefits of preventing nonfatal yet symptomatic infections. Nea
Autor:
Ronald J. Moleski, Gene A. Gibson, R. Jake Jacobs, Thomas A. Paivanas, Gary Milkovich, John Reitan, Susan Wyant, David M. Dunning
Publikováno v:
Pharmacotherapy. 20:1432-1440
Study Objective. To compare rates of adverse events with filgrastim versus sargramostim when given prophylactically to patients receiving myelosuppressive chemotherapy. Design. Retrospective review with center crossover. Setting. Ten United States ou
Publikováno v:
Journal of Food Protection. 63:768-774
Foodborne transmission is an important means of hepatitis A infection that may be reduced through vaccination of food service workers (FSWs). Several states are considering actions to encourage or mandate FSW vaccination, but the cost effectiveness o